Literature DB >> 17438529

Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma.

E Tchougounova1, M Kastemar, D Bråsäter, E C Holland, B Westermark, L Uhrbom.   

Abstract

In a subset of gliomas, the platelet-derived growth factor (PDGF) signaling pathway is perturbed. This is usually an early event occurring in low-grade tumors. In high-grade gliomas, the subsequent loss of the INK4a-ARF locus is one of the most common mutations. Here, we dissected the separate roles of Ink4a and Arf in PDGFB-induced oligodendroglioma development in mice. We found that there were differential functions of the two tumor suppressor genes. In tumors induced from astrocytes, both Ink4a-loss and Arf-loss caused a significantly increased incidence compared to wild-type mice. In tumors induced from glial progenitor cells there was a slight increase in tumor incidence in Ink4a-/- mice and Ink4a-Arf-/- mice compared to wild-type mice. In both progenitor cells and astrocytes, Arf-loss caused a pronounced increase in tumor malignancy compared to Ink4a-loss. Hence, Ink4a-loss contributed to tumor initiation from astrocytes and Arf-loss caused tumor progression from both glial progenitor cells and astrocytes. Results from in vitro studies on primary brain cell cultures suggested that the PDGFB-induced activation of the mitogen-activated protein kinase pathway via extracellular signal-regulated kinase was involved in the initiation of low-grade oligodendrogliomas and that the additional loss of Arf may contribute to tumor progression through increased levels of cyclin D1 and a phosphoinositide 3-kinase-dependent activation of p70 ribosomal S6 kinase causing a strong proliferative response of tumor cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17438529     DOI: 10.1038/sj.onc.1210455

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  43 in total

1.  Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease.

Authors:  Barbara S Paugh; Chunxu Qu; Chris Jones; Zhaoli Liu; Martyna Adamowicz-Brice; Junyuan Zhang; Dorine A Bax; Beth Coyle; Jennifer Barrow; Darren Hargrave; James Lowe; Amar Gajjar; Wei Zhao; Alberto Broniscer; David W Ellison; Richard G Grundy; Suzanne J Baker
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

2.  PDGF-B Can sustain self-renewal and tumorigenicity of experimental glioma-derived cancer-initiating cells by preventing oligodendrocyte differentiation.

Authors:  Yiwen Jiang; Maria Boije; Bengt Westermark; Lene Uhrbom
Journal:  Neoplasia       Date:  2011-06       Impact factor: 5.715

3.  Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis.

Authors:  Berenice Ortiz; Armida W M Fabius; Wei H Wu; Alicia Pedraza; Cameron W Brennan; Nikolaus Schultz; Kenneth L Pitter; Jacqueline F Bromberg; Jason T Huse; Eric C Holland; Timothy A Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 11.205

Review 4.  Review: insights gained from modelling high-grade glioma in the mouse.

Authors:  S L Rankin; G Zhu; S J Baker
Journal:  Neuropathol Appl Neurobiol       Date:  2012-06       Impact factor: 8.090

5.  Low Concentration Microenvironments Enhance the Migration of Neonatal Cells of Glial Lineage.

Authors:  Richard A Able; Celestin Ngnabeuye; Cade Beck; Eric C Holland; Maribel Vazquez
Journal:  Cell Mol Bioeng       Date:  2012-06       Impact factor: 2.321

Review 6.  Mouse models of glioblastoma: lessons learned and questions to be answered.

Authors:  Loury Janbazian; Jason Karamchandani; Sunit Das
Journal:  J Neurooncol       Date:  2014-02-13       Impact factor: 4.130

7.  De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.

Authors:  David Akhavan; Alexandra L Pourzia; Alex A Nourian; Kevin J Williams; David Nathanson; Ivan Babic; Genaro R Villa; Kazuhiro Tanaka; Ali Nael; Huijun Yang; Julie Dang; Harry V Vinters; William H Yong; Mitchell Flagg; Fuyuhiko Tamanoi; Takashi Sasayama; C David James; Harley I Kornblum; Tim F Cloughesy; Webster K Cavenee; Steven J Bensinger; Paul S Mischel
Journal:  Cancer Discov       Date:  2013-03-26       Impact factor: 39.397

8.  The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.

Authors:  Daniela F Quail; Robert L Bowman; Leila Akkari; Marsha L Quick; Alberto J Schuhmacher; Jason T Huse; Eric C Holland; James C Sutton; Johanna A Joyce
Journal:  Science       Date:  2016-05-20       Impact factor: 47.728

9.  Tumor progression and oncogene addiction in a PDGF-B-induced model of gliomagenesis.

Authors:  Filippo Calzolari; Irene Appolloni; Evelina Tutucci; Sara Caviglia; Marta Terrile; Giorgio Corte; Paolo Malatesta
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

10.  Histidine-rich glycoprotein can prevent development of mouse experimental glioblastoma.

Authors:  Maria Kärrlander; Nanna Lindberg; Tommie Olofsson; Marianne Kastemar; Anna-Karin Olsson; Lene Uhrbom
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.